Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Celldex ends esophageal program despite hitting primary endpoint
The biotech showed the candidate depletes mast cells in the GI tract, but that positive finding was overshadowed by its failure to improve symptoms.
Nick Paul Taylor
Aug 20, 2025 6:42am
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
Rapt Tx cuts staff for 2nd time in less than a year
Jun 4, 2025 4:46pm
Merck made $3B offer for MoonLake—and could revive interest: FT
Jun 3, 2025 9:25am
Boston biotech banks $90M for next-gen bispecifics
Feb 14, 2025 10:10am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
